Bahar Ramezanpour, Ph.D

Head of Business Development

Bahar Ramezanpour holds a Ph.D. in disruptive innovation by genetically modified technologies from the University of Amsterdam and Erasmus University of Rotterdam under the supervision of Prof. ab Osterhaus and dr. Eric Claassen.

She joined the HUB in 2017 with a background in MPA, infectious diseases and genetically modified vaccines. Prior to joining the HUB, she served as Director Business Development at ViroNovative B.V. and Sovalacc B.V., biotechnology company and life sciences consultancy respectively. In these positions, she was responsible for all the aspect of business development, including out-licensing and alliance management. Furthermore, she has been involved in the start-up and growth of several business ventures in the life sciences sector.

October 01, 2019 Hubrecht Organoid Technology and MIMETAS to d... Leiden, Utrecht September 2019 MIMETAS and Hubrecht Organoid Technology (HUB) announce that they entered into a strategi... read more
July 17, 2019 Epistem license Hubrecht Organoid Technology ... Epistem license Hubrecht Organoid Technology to expand preclinical toxicology service portfolio Manchester, 16th July, 2... read more
July 09, 2019 ‘Het gaat alleen sneller als er geld bij ko... Hubrecht Organoid Technology, kortweg HUB, is als start-up ontstaan op de Uithof, de universiteitscampus in Utrecht. Het... read more